Agios Pharmaceutical (AGIO) 52.29 $AGIO
Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
GlobeNewswire - Tue Sep 20, 3:01PM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 505,617 shares at the public offering price of $44.50 per share. The exercise of the option to purchase additional shares brought the total number of shares of common stock sold by Agios to 3,876,403 shares and increased the amount of gross proceeds raised in the offering, before underwriting discounts and estimated expenses of the offering, to approximately $173 million.
JPM: 66.84 (+0.38), AGIO: 52.29 (+2.46)
Agios Announces Pricing of $150 Million Public Offering of Common Stock
GlobeNewswire - Wed Sep 14, 7:14PM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it has priced an underwritten public offering of 3,370,786 shares of common stock at a price to the public of $44.50 per share, before underwriting discounts, which would result in aggregate gross proceeds of approximately $150 million. All of the shares in the offering are to be sold by Agios. Agios has also granted the underwriters a 30-day option to purchase up to an additional 505,617 shares of common stock on the same terms and conditions. Closing of the offering is expected to occur on or about September 20, 2016, subject to customary closing conditions.
JPM: 66.84 (+0.38), AGIO: 52.29 (+2.46)
Agios Announces Proposed Offering of Common Stock
GlobeNewswire - Tue Sep 13, 3:13PM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it is offering to sell, subject to market and other conditions, up to $150 million of its common stock in an underwritten public offering. Agios also intends to grant the underwriters a 30-day option to purchase from it up to an additional $22.5 million of shares. All of the shares in the offering are to be sold by Agios. The proceeds of the offering are expected to be used to fund the company's clinical and research development activities. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
JPM: 66.84 (+0.38), AGIO: 52.29 (+2.46)
InvestorsObserver releases covered-call reports for Valeant Pharmaceuticals, Agios Pharmaceuticals, Apache Corporation, FireEye and Coca-Cola Enterprises
PR Newswire - Thu Sep 08, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AGIO, APA, CCE, FEYE, and VRX.
VRX: 26.97 (+0.64), FEYE: 13.81 (+0.26), APA: 60.89 (+3.40), AGIO: 52.29 (+2.46), CCE: 39.70 (-0.05)
Agios' (AGIO) Partner Celgene to File for Enasidenib, Stock Up
Zacks Equity Research - Zacks Investment Research - Thu Sep 08, 8:09AM CDT
Agios Pharmaceuticals' (AGIO) partner Celgene will seek for an FDA approval of enasidenib for relapsed and/or refractory acute myeloid leukemia by 2016 end.
GERN: 2.25 (+0.20), AGIO: 52.29 (+2.46), CORT: 6.22 (+0.26), CELG: 109.58 (+1.16)
Blog Coverage Celgene Partner of Agios Pharma Plans NDA to Get FDA Approval for Blood Cancer Drug AG 221
ACCESSWIRE - Thu Sep 08, 8:02AM CDT
LONDON, UK / ACCESSWIRE / September 8, 2016 / Active Wall St. blog coverage looks at the headline from Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) as the company announced on September 7, 2016, that its partner Celgene Corp. (NASDAQ: CELG) would be filing a new drug application (NDA) for Agios' drug enasidenib, also known as AG-221, with the U.S. Food and Drug Administration (FDA) for approval. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
AGIO: 52.29 (+2.46), CELG: 109.58 (+1.16), CELGZ: 1.25 (+0.05)
Agios to Present at Morgan Stanley Global Healthcare Conference Tuesday, September 13, 2016
GlobeNewswire - Tue Sep 06, 7:11AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company is scheduled to present at the Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 13, 2016 at 2:05 p.m. ET.
AGIO: 52.29 (+2.46), MS: 31.92 (+0.22)
How These Biotech Stocks are Faring? -- Progenics Pharma, Peregrine Pharma, Agios Pharma, and Cara Therapeutics
PR Newswire - Fri Aug 26, 6:50AM CDT
Stock-Callers.com has initiated research reports on the following Biotech companies: Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Agios Pharmaceuticals Inc. (NASDAQ: AGIO), and Cara Therapeutics Inc. (NASDAQ: CARA). On Wednesday, August 24, 2016, the iShares NASDAQ Biotechnology ETF (IBB) plummeted 3% after Democratic presidential candidate Hillary Clinton tweeted about the price hikes on EpiPens. Register now and get full and free access to our downloadable research reports on these stocks at:
CARA: 7.51 (+0.24), PGNX: 6.24 (+0.06), PPHM: 0.42 (+0.04), AGIO: 52.29 (+2.46)
Agios Appoints Andrew Hirsch as Chief Financial Officer
GlobeNewswire - Tue Aug 16, 6:30AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that Andrew Hirsch is joining the company as chief financial officer, effective September 19, 2016. Mr. Hirsch has more than 20 years of experience in a range of strategic and operating roles in the biotechnology sector, most recently having served as president and chief executive officer of BIND Therapeutics.
AGIO: 52.29 (+2.46), BIND: 0.78 (-0.09)
Agios (AGIO) Q2 Loss Wider than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 10:10AM CDT
Agios Pharmaceuticals (AGIO) reported a wider-than-expected second-quarter 2016 loss of $1.47 per share.
GERN: 2.25 (+0.20), AGIO: 52.29 (+2.46), ANIK: 47.93 (+0.34), CELG: 109.58 (+1.16)
Agios to Present at Canaccord Genuity 36th Annual Growth Conference Wednesday, August 10, 2016
GlobeNewswire - Fri Aug 05, 6:01AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company is scheduled to present at the Canaccord Genuity 36th Annual Growth Conference in Boston on Wednesday, August 10, 2016 at 8:00 a.m. ET.
AGIO: 52.29 (+2.46)
Agios (AGIO) Reports Wider-than-Expected Loss in Q2
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 7:50AM CDT
Agios (AGIO) posted wider-than-expected loss in the second quarter of 2016.
AGIO: 52.29 (+2.46)
Agios Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 6:01AM CDT
- Data from PKR Activators at EHA Demonstrated Proof-of-Concept for AG-348 and Proof-of-Mechanism for AG-519; Program Moving Toward Pivotal Development in PK Deficiency with Molecule Selection by Year-End 2016 -
AGIO: 52.29 (+2.46)
Medical Product Stock Earnings on Aug 4: NXTM, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 9:56AM CDT
Here, we take a look at four Medical product stocks set to report their quarterly figures on Aug 4.
NXTM: 24.80 (+0.59), AGIO: 52.29 (+2.46), ATRC: 15.96 (-0.01), HRC: 59.75 (+0.52)
Will Agios (AGIO) Disappoint Estimates in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 10:23AM CDT
Agios Pharmaceuticals (AGIO), which is set to report second-quarter 2016 results on Aug 4, had posted a positive surprise of 11.59% last quarter.
ICPT: 168.78 (-1.23), AGIO: 52.29 (+2.46), EXEL: 14.74 (+0.58), CELG: 109.58 (+1.16)
Agios to Webcast Conference Call of Second Quarter 2016 Financial Results on August 4, 2016
GlobeNewswire - Thu Jul 28, 3:01PM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2016 at 8:30 a.m. ET to report its second quarter 2016 financial results and discuss recent clinical development and corporate activities.
AGIO: 52.29 (+2.46)
Agios Reports Favorable Phase II PK Deficiency Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:56AM CDT
Agios Pharmaceuticals (AGIO) reported encouraging initial data from an ongoing phase II DRIVE-PK study on pyruvate kinase deficiency candidate AG-348.
PFE: 34.28 (+0.47), RTRX: 23.75 (+0.33), AGIO: 52.29 (+2.46), BMY: 55.93 (+0.37)
Agios Reports Initial Data from Phase 1 Study of AG-519 in Healthy Volunteers
GlobeNewswire - Thu Jun 09, 8:21AM CDT
- Data Demonstrate Favorable Safety Profile with up to 14 Days of Daily Dosing -
AGIO: 52.29 (+2.46)
What Investors Think of These Biotech Stocks? - Genocea Biosciences, BioDelivery Sciences Intl., INSYS Therapeutics, and Agios Pharma
PR Newswire - Thu Jun 02, 7:20AM CDT
Restructuring activities within the Biotech industry as well as the nearing U.S. presidential election continues to affect the overall condition of firms in this space. But despite the uncertainties, investors see potential growth in select companies that. Today, ActiveWallSt.com reviews the performances of the following equities: Genocea Biosciences Inc. (NASDAQ: GNCA), BioDelivery Sciences International Inc. (NASDAQ: BDSI), INSYS Therapeutics Inc. (NASDAQ: INSY), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Click below to get your complimentary trade alerts:
BDSI: 2.43 (+0.04), INSY: 13.27 (-0.48), AGIO: 52.29 (+2.46), GNCA: 5.46 (unch)
Agios to Host Conference Call from the 21st Congress of the European Hematology Association
GlobeNewswire - Wed Jun 01, 6:01AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Saturday, June 11, 2016 at 9:30 a.m. ET to discuss clinical and preclinical data presented at the 21st Congress of the European Hematology Association (EHA) taking place June 9-12, 2016 in Copenhagen.
AGIO: 52.29 (+2.46)
Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
GlobeNewswire - Tue Sep 20, 3:01PM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 505,617 shares at the public offering price of $44.50 per share. The exercise of the option to purchase additional shares brought the total number of shares of common stock sold by Agios to 3,876,403 shares and increased the amount of gross proceeds raised in the offering, before underwriting discounts and estimated expenses of the offering, to approximately $173 million.
JPM: 66.84 (+0.38), AGIO: 52.29 (+2.46)
Agios Announces Pricing of $150 Million Public Offering of Common Stock
GlobeNewswire - Wed Sep 14, 7:14PM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it has priced an underwritten public offering of 3,370,786 shares of common stock at a price to the public of $44.50 per share, before underwriting discounts, which would result in aggregate gross proceeds of approximately $150 million. All of the shares in the offering are to be sold by Agios. Agios has also granted the underwriters a 30-day option to purchase up to an additional 505,617 shares of common stock on the same terms and conditions. Closing of the offering is expected to occur on or about September 20, 2016, subject to customary closing conditions.
JPM: 66.84 (+0.38), AGIO: 52.29 (+2.46)
Agios Announces Proposed Offering of Common Stock
GlobeNewswire - Tue Sep 13, 3:13PM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it is offering to sell, subject to market and other conditions, up to $150 million of its common stock in an underwritten public offering. Agios also intends to grant the underwriters a 30-day option to purchase from it up to an additional $22.5 million of shares. All of the shares in the offering are to be sold by Agios. The proceeds of the offering are expected to be used to fund the company's clinical and research development activities. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
JPM: 66.84 (+0.38), AGIO: 52.29 (+2.46)
InvestorsObserver releases covered-call reports for Valeant Pharmaceuticals, Agios Pharmaceuticals, Apache Corporation, FireEye and Coca-Cola Enterprises
PR Newswire - Thu Sep 08, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AGIO, APA, CCE, FEYE, and VRX.
VRX: 26.97 (+0.64), FEYE: 13.81 (+0.26), APA: 60.89 (+3.40), AGIO: 52.29 (+2.46), CCE: 39.70 (-0.05)
Agios' (AGIO) Partner Celgene to File for Enasidenib, Stock Up
Zacks Equity Research - Zacks Investment Research - Thu Sep 08, 8:09AM CDT
Agios Pharmaceuticals' (AGIO) partner Celgene will seek for an FDA approval of enasidenib for relapsed and/or refractory acute myeloid leukemia by 2016 end.
GERN: 2.25 (+0.20), AGIO: 52.29 (+2.46), CORT: 6.22 (+0.26), CELG: 109.58 (+1.16)
Blog Coverage Celgene Partner of Agios Pharma Plans NDA to Get FDA Approval for Blood Cancer Drug AG 221
ACCESSWIRE - Thu Sep 08, 8:02AM CDT
LONDON, UK / ACCESSWIRE / September 8, 2016 / Active Wall St. blog coverage looks at the headline from Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) as the company announced on September 7, 2016, that its partner Celgene Corp. (NASDAQ: CELG) would be filing a new drug application (NDA) for Agios' drug enasidenib, also known as AG-221, with the U.S. Food and Drug Administration (FDA) for approval. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
AGIO: 52.29 (+2.46), CELG: 109.58 (+1.16), CELGZ: 1.25 (+0.05)
Agios to Present at Morgan Stanley Global Healthcare Conference Tuesday, September 13, 2016
GlobeNewswire - Tue Sep 06, 7:11AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company is scheduled to present at the Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 13, 2016 at 2:05 p.m. ET.
AGIO: 52.29 (+2.46), MS: 31.92 (+0.22)
How These Biotech Stocks are Faring? -- Progenics Pharma, Peregrine Pharma, Agios Pharma, and Cara Therapeutics
PR Newswire - Fri Aug 26, 6:50AM CDT
Stock-Callers.com has initiated research reports on the following Biotech companies: Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Agios Pharmaceuticals Inc. (NASDAQ: AGIO), and Cara Therapeutics Inc. (NASDAQ: CARA). On Wednesday, August 24, 2016, the iShares NASDAQ Biotechnology ETF (IBB) plummeted 3% after Democratic presidential candidate Hillary Clinton tweeted about the price hikes on EpiPens. Register now and get full and free access to our downloadable research reports on these stocks at:
CARA: 7.51 (+0.24), PGNX: 6.24 (+0.06), PPHM: 0.42 (+0.04), AGIO: 52.29 (+2.46)
Agios Appoints Andrew Hirsch as Chief Financial Officer
GlobeNewswire - Tue Aug 16, 6:30AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that Andrew Hirsch is joining the company as chief financial officer, effective September 19, 2016. Mr. Hirsch has more than 20 years of experience in a range of strategic and operating roles in the biotechnology sector, most recently having served as president and chief executive officer of BIND Therapeutics.
AGIO: 52.29 (+2.46), BIND: 0.78 (-0.09)
Agios (AGIO) Q2 Loss Wider than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 10:10AM CDT
Agios Pharmaceuticals (AGIO) reported a wider-than-expected second-quarter 2016 loss of $1.47 per share.
GERN: 2.25 (+0.20), AGIO: 52.29 (+2.46), ANIK: 47.93 (+0.34), CELG: 109.58 (+1.16)
Agios to Present at Canaccord Genuity 36th Annual Growth Conference Wednesday, August 10, 2016
GlobeNewswire - Fri Aug 05, 6:01AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company is scheduled to present at the Canaccord Genuity 36th Annual Growth Conference in Boston on Wednesday, August 10, 2016 at 8:00 a.m. ET.
AGIO: 52.29 (+2.46)
Agios (AGIO) Reports Wider-than-Expected Loss in Q2
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 7:50AM CDT
Agios (AGIO) posted wider-than-expected loss in the second quarter of 2016.
AGIO: 52.29 (+2.46)
Agios Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 6:01AM CDT
- Data from PKR Activators at EHA Demonstrated Proof-of-Concept for AG-348 and Proof-of-Mechanism for AG-519; Program Moving Toward Pivotal Development in PK Deficiency with Molecule Selection by Year-End 2016 -
AGIO: 52.29 (+2.46)
Medical Product Stock Earnings on Aug 4: NXTM, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 9:56AM CDT
Here, we take a look at four Medical product stocks set to report their quarterly figures on Aug 4.
NXTM: 24.80 (+0.59), AGIO: 52.29 (+2.46), ATRC: 15.96 (-0.01), HRC: 59.75 (+0.52)
Will Agios (AGIO) Disappoint Estimates in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 10:23AM CDT
Agios Pharmaceuticals (AGIO), which is set to report second-quarter 2016 results on Aug 4, had posted a positive surprise of 11.59% last quarter.
ICPT: 168.78 (-1.23), AGIO: 52.29 (+2.46), EXEL: 14.74 (+0.58), CELG: 109.58 (+1.16)
Agios to Webcast Conference Call of Second Quarter 2016 Financial Results on August 4, 2016
GlobeNewswire - Thu Jul 28, 3:01PM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2016 at 8:30 a.m. ET to report its second quarter 2016 financial results and discuss recent clinical development and corporate activities.
AGIO: 52.29 (+2.46)
Agios Reports Favorable Phase II PK Deficiency Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:56AM CDT
Agios Pharmaceuticals (AGIO) reported encouraging initial data from an ongoing phase II DRIVE-PK study on pyruvate kinase deficiency candidate AG-348.
PFE: 34.28 (+0.47), RTRX: 23.75 (+0.33), AGIO: 52.29 (+2.46), BMY: 55.93 (+0.37)
Agios Reports Initial Data from Phase 1 Study of AG-519 in Healthy Volunteers
GlobeNewswire - Thu Jun 09, 8:21AM CDT
- Data Demonstrate Favorable Safety Profile with up to 14 Days of Daily Dosing -
AGIO: 52.29 (+2.46)
What Investors Think of These Biotech Stocks? - Genocea Biosciences, BioDelivery Sciences Intl., INSYS Therapeutics, and Agios Pharma
PR Newswire - Thu Jun 02, 7:20AM CDT
Restructuring activities within the Biotech industry as well as the nearing U.S. presidential election continues to affect the overall condition of firms in this space. But despite the uncertainties, investors see potential growth in select companies that. Today, ActiveWallSt.com reviews the performances of the following equities: Genocea Biosciences Inc. (NASDAQ: GNCA), BioDelivery Sciences International Inc. (NASDAQ: BDSI), INSYS Therapeutics Inc. (NASDAQ: INSY), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Click below to get your complimentary trade alerts:
BDSI: 2.43 (+0.04), INSY: 13.27 (-0.48), AGIO: 52.29 (+2.46), GNCA: 5.46 (unch)
Agios to Host Conference Call from the 21st Congress of the European Hematology Association
GlobeNewswire - Wed Jun 01, 6:01AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Saturday, June 11, 2016 at 9:30 a.m. ET to discuss clinical and preclinical data presented at the 21st Congress of the European Hematology Association (EHA) taking place June 9-12, 2016 in Copenhagen.
AGIO: 52.29 (+2.46)
